tbuckley/cabot-search huggingface dataset:
Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group
Authors: D. Arnold, A. Hinke, A. C. Reinacher-Schick, W. Schmiegel, U. Graeven, S. Kubicka, L. Fischer von Weikersthal, N. Moosmann, H. Schmoll, V. Heinemann
Journal: Journal of Clinical Oncology (2008)

4067 Background: Response rate captures anti-tumor efficacy and displays the percentage of patients with relevant tumor shrinkage, but does not address the magnitude of response.Therefore, Waterfall plot analyses (WPA) have been used in a single examination for ACRC with conventional chemotherapy (Grothey, ASCO GI ´07). To assess activity of different regimen with ‘targeted‘ drugs, WPA were done on 2 similarly designed rand. 1st line ACRC trials with bevacizumab (B) or cetuximab (C): AIO 0604: XELOX-B vs. XELIRI-B (Schmiegel, ASCO ´07; N=255) and AIO 0104: XELOX-C vs. XELIRI-C (Heinemann, ESMO ´06; N=185). Methods: The percentage change according to RECIST criteria from baseline was evaluated at time of best response. Average reduction in tumor burden (ARTB) was calculated as difference in waterfall area under curve divided by the number of pts. In addition, median reduction in tumor burden (MRTB), which might be preferable as the inherent ceiling effects preclude normal distribution, was calculated. From the 4 arms, pooled analysis was done: XELOX vs. XELIRI (indep. from targeted agent), and B vs. C (indep. from chemotherapy). Results: Data from 199 pts (81% of all pts incl.) of the 0604 trial and from 122 pts (69% of all pts) of the 0104 trial, with measurable disease and at least one confirmation restaging were available. Pooled analysis included all 321 pts: XELOX 156, XELIRI 165; 199 with B, 122 with C. WPA displayed similar tumor growth/ shrinkage rates: 6%/88%(XELOX-B), 8%/87% (XELIRI-B), 4%/93% (XELOX-C), and 8%/86% (XELIRI- C) of pts. Pooled analysis resulted in different ARTB and MRTB (see table). Conclusions: WPA with ARTB and MRTB may provide additional information, compared to rates of tumor reduction. The results suggest a larger benefit for C containing combinations, but should be interpreted with caution due to the non-randomized comparison, limited sample size and un-preplanned character of the analysis. XELIRI XELOX Beva Cetux ARTB (%) 31.2 34.7 29.2 38.9 MRTB (%) 31 33 30 35 p 0.29 0.009 p value: Wilcoxon-Mann-Whitney test, 2-sided Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Merck, Pfizer Oncology, Roche, Roche Pharma, sanofi-aventis Merck, Roche, Roche GmbH, sanofi-aventis
Survivorship: Nutrition and Weight Management, Version 2.2014
Authors: Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2014)

Healthy lifestyle habits have been associated with improved health outcomes and quality of life and, for some cancers, a reduced risk of recurrence and death. The NCCN Guidelines for Survivorship therefore recommend that cancer survivors be encouraged to achieve and maintain a healthy lifestyle, including attention to weight management, physical activity, and dietary habits. This section of the NCCN Guidelines focuses on recommendations regarding nutrition, weight management, and supplement use in survivors. Weight management recommendations are based on the survivor's body mass index and include discussions of nutritional, weight management, and physical activity principles, with referral to community resources, dietitians, and/or weight management programs as needed.
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial
Authors: Giora Weisz, Philippe Généreux, Andres Iñiguez, Aleksander Zurakowski, Michael Shechter, Karen P Alexander, Ovidiu Dressler, Anna Osmukhina, Stefan James, E Magnus Ohman, Ori Ben-Yehuda, Ramin Farzaneh-Far, Gregg W Stone
Journal: The Lancet (2015)
Late-breaking abstract: Noninvasive positive airway pressure ventilation and risk of pressure ulcers in patients with acute respiratory failure
Authors: Giovanni Ferrari, Valter Gallo, Francesco Panero, Fabrizio Elia, Franco Aprà
Journal: European Respiratory Journal (2014)

Background: Noninvasive ventilation (NIV) improves the outcome of patients with acute respiratory failure; however patient9s discomfort due to mask intolerance and skin pressure ulcers may be a quite common cause of failure. Aim of our study was to seek for variables associated to the development of NIV related pressure ulcers.  Methods: 170 patients, who underwent NIV for acute respiratory failure, were analyzed. Demographic and clinical variables were collected as well as type of pressure ulcer, interface, mode and duration of ventilation.  Results: Our clinical cohort was made up of 99 male patients (58.2%), median age (interquartile range) was 75.2 (67.7-80.7) years. Median duration of NIV treatment was 3 (2-6) days. The oro-nasal mask was used in half of cases, while full-face and helmet in 35.3% and 14.7%. 46/170 (27.1%) patients experienced a NIV-related pressure ulcer. In the univariate analysis, the oro-nasal mask, duration of ventilation, type of feeding support and chronic use of steroids were significantly associated to the risk of ulcers. In the multivariate model, oro-nasal mask (OR=6.91, IC95% 1.77-26.90, p  Conclusions: Pressure ulcers represent a common complication of NIV. Some determinants could be matter of both preventive interventions and further investigation.
Abstract 13573: Trends, Predictors and Outcomes of Intracranial Hemorrhage in Patients With Left Ventricular Assist Device
Authors: Muhammad Shahreyar, Sanjay Bhandari, Mobin Malik, Vijayadershan Muppidi, Geetanjali Dang, Navdeep Gupta, Nasir Sulemanjee, Francis X Downey, Arshad Jahangir
Journal: Circulation (2015)

Introduction: Left ventricular assist device (LVAD) is being increasingly utilized in patients with advanced heart failure both as bridge to heart transplantation and as destination therapy. Intracranial hemorrhage (ICH) is one of major complications associated with LVAD. However, current trends on utilization of LVAD and associated ICH in real world practice are not known. Methods: We analyzed patients in the Nationwide Inpatient Sample (NIS) between 2007 and 2011. Heart failure patients with LVAD were identified from the database and patients with discharge diagnosis of ICH were compared to those without ICH. Trends and outcomes of ICH in patients with LVAD were analyzed. In addition, predictors of ICH were identified using a multivariate regression model. Results: We identified 20,443 discharges with a primary diagnosis of heart failure with LVAD of which 447 patients had a co-diagnosis of ICH. We saw a significant increase in discharge diagnosis of heart failure with LVAD from 1232 discharges in 2007 to 6308 in 2011 (p&amp;lt0.001)(Figure). However, the incidence of ICH in this patient population decreased from 3.9% in 2007 to 2.4% in 2011. On multivariate analysis, in-hospital mortality was significantly higher in the ICH group (OR: 9.5, P=0.0001). After adjustment for potential confounders age &amp;lt35 years (OR: 2.4, P=0.01) and a rising Charlson co-morbidity index score were independent predictors of ICH whereas presence of diabetes (OR: 0.05, P=0.001), chronic lung disease (OR:0.07, P=0.001), renal disease (OR: 0.09, P=0.001) and peripheral vascular disease (OR: 0.12, P=0.002) were found to be protective of ICH. Conclusions: Our analysis indicates an increasing trend in utilization of LVAD but a decrease in incidence of ICH over the same period. ICH was found to increase risk of mortality by nearly 10 fold. Increasing comorbidity burden increases the risk of ICH whereas age and certain individual co-morbidities appear to have a paradoxical effect on risk of ICH.
The emerging role of the contractile and vascular reserves in pulmonary arterial hypertension
Authors: Juan C. Grignola, Enric Domingo
Journal: European Respiratory Journal (2015)

We read with great interest the recent article by Sharma et al. [1] on the evaluation of right ventricular (RV) reserve in pulmonary arterial hypertension (PAH) by the dobutamine stress test. Their work highlights the potential clinical value of the RV systolic reserve into the evaluation of PAH patients beyond resting measurements. Sharma et al. [1] reported that RV contractile reserve (tricuspid annular plane systolic excursion (TAPSE) and tricuspid annulus systolic myocardial velocity ( S ′)) is markedly attenuated in PAH patients and correlates with exercise capacity. Although the merit of the work is in assessing RV contractile reserve by direct functional parameters, there are some topics that deserve discussion. Patients with PAH exhibit markedly diminished RV contractile reserve and pulmonary arterial vascular reserve <http://ow.ly/L7or6>
LIPIDS AND IMMUNOLOGICAL REACTIONS
Authors: Frank L. Horsfall, Kenneth Goodner
Journal: The Journal of Experimental Medicine (1936)

1. Specific precipitates resulting from the interaction of the homologous capsular polysaccharide and Type I antipneumococcus horse and rabbit sera have been analyzed by gasometric micro methods for total nitrogen, lipid nitrogen, and lipid carbon. 2. Lipid may, under certain conditions, form as much as 51 per cent or as little as 4 per cent by weight of specific precipitates. 3. The total lipid content of specific precipitates, within the range studied, is entirely independent of the protein content. 4. Lipid nitrogen forms a very small but detectable portion of the total nitrogen of precipitates. 5. The absolute lipid content of precipitates is a function of the concentration of lipid in the reacting mixture prior to precipitation, and seems to be governed by the laws of adsorption phenomena.
Clarifying the difference between mandatory recording and mandatory reporting of FGM
Authors: Helen Hartley
Journal: BMJ (2015)

There seems to be confusion among doctors regarding the difference between the new rules on mandatory recording and mandatory reporting of female genital mutilation (FGM).1

All cases of FGM in patients under the age of 18 must be reported to the police, ideally by the close of the next working day but no later than a month after treating …
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study
Authors: D. Hompes, A. D’Hoore, E. Van Cutsem, W. Ceelen, M. Peeters, K. Van der Speeten, C. Bertrand, J. Kerger, H. Legendre
Journal: Journal of Clinical Oncology (2009)

4101 Background: Up to 25% of patients with metastatic CRC present with peritoneal carcinomatosis (PC) as the only site of metastases. The concept of Complete Cytoreductive Surgery (CCRS) followed by Hyperthermia and Intraperitoneal Chemotherapy (HIPEC) was developed, aiming for locoregional disease control and long-term survival. Methods: This prospective multicentre registry included 48 patients (M/F ratio 17/31) with PC from CRC, who underwent CCRS and HIPEC with oxaliplatin(460mg/m 2 ). In 72.9% of patients the primary tumor had been previously resected. Median PCI (peritoneal cancer index) was 11 [1–22], with a median of 6 [1–11] abdominal regions involved and a median lesion size score of 3 [1–3]. In 11 cases associated lymph nodes (63.6% mesenteric, 27.3% para-aortic) were resected. To obtain CCRS a median of 2 [2–6] organs needed to be resected, with anterior resection in 45.8%, total colectomy in 8.3% and small bowel resection in 12.5% of cases. A median of 1 [0–6] anastomosis was performed per patient, of which one third were low and 82.1% were performed after HIPEC. Eleven ileostomies and 5 colostomies were constructed. Results: Median operation time was 460min.[125–840], with a median blood loss of 475ml [2- 6000]. HIPEC posed few procedural problems. There was no postoperative mortality. Complication rate was 52.1%, with 18 intra- and 17 extra-abdominal complications. Anastomotic leakage occurred in 10.4% of patients, bleeding in 6.3% and prolonged ileus in 22.9%. Median hospital stay was 20 [5–65] days. Occurrence of intra-abdominal complications significantly affected hospital stay (p=0.0012), but no risk factors for occurrence of postoperative complications could be clearly identified. Median follow-up was 22.7 [3.2–55.7] months, with 91.7% 2-year overall survival. Progression-free survival at 2 years is 64.6%, with PC recurrence in 29.2% of patients and other metastatic disease in 25%. Multivariate analysis only retained the CEA-level as a significant prognostic factor (p=0.0065). Conclusions: CCRS followed by HIPEC for PC of colorectal origin is safe and has longer than expected PFS and OS. No significant financial relationships to disclose.
Surgical outcomes with non-invasive presurgical evaluation in MRI determined bilateral mesial temporal sclerosis: A retrospective cohort study
Authors: Sangeeta Ravat, Prajwal Rao, Vivek Iyer, Dattatraya Muzumdar, Urvashi Shah, Shraddha Shah, Neeraj Jain, Yogesh Godge
Journal: International Journal of Surgery (2015)
TCT-97 Transcatheter Aortic Valve Replacement Using the Self-Expanding Bioprosthesis: First Report from the Transcatheter Valve Therapies Registry
Authors: Jeffrey Popma, Michael J. Reardon, Paul Sorajja, Wilson Y. Szeto, James Hermiller, Stanley J. Chetcuti, Susheel Kodali, David Adams
Journal: Journal of the American College of Cardiology (2015)
A Strategy to Reduce General Surgery Resident Attrition
Authors: Molly A. Wasserman
Journal: JAMA Surgery (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Changing epidemiology of group B streptococcal infections among adults in Iceland: 1975–2014
Authors: E.S. Björnsdóttir, E.R. Martins, H. Erlendsdóttir, G. Haraldsson, J. Melo-Cristino, K.G. Kristinsson, M. Ramirez
Journal: Clinical Microbiology and Infection (2015)
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
Authors: Carolyn D. Runowicz, Corinne R. Leach, N. Lynn Henry, Karen S. Henry, Heather T. Mackey, Rebecca L. Cowens-Alvarado, Rachel S. Cannady, Mandi L. Pratt-Chapman, Stephen B. Edge, Linda A. Jacobs, Arti Hurria, Lawrence B. Marks, Samuel J. LaMonte, Ellen Warner, Gary H. Lyman, Patricia A. Ganz
Journal: Journal of Clinical Oncology (2015)

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made. This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. Copyright © 2015 American Cancer Society and American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.
Abstract 17913: The Long Non-coding Rna Malat1 Regulates Atherosclerosis in vivo
Authors: Katharina M Michalik, Sebastian Cremer, Ariane Fischer, Marion Muhly-Reinholz, Larissa Pfisterer, Wolfgang Poller, Rainier Boon, Andreas M Zeiher, Stefanie Dimmeler
Journal: Circulation (2015)

Long non-coding RNAs (lncRNAs) have been described to play a role in many biological processes, including epigenetic regulation of gene expression. We previously showed that the lncRNA MALAT1 regulates angiogenesis. Since MALAT1 is induced by atheroprotective laminar shear stress, we determined whether MALAT1 regulates atherosclerosis. To address this question, we generated MALAT -/- ApoE -/- mice that were fed with a high fat diet for 12 weeks. Genetic deletion of MALAT1 in ApoE-/- mice increased plaque size as defined by oil red positive area in the aortic arch (+28.4+12%; n=5, p&lt;0.05). However, pharmacological inhibition of MALAT1 by GapmeRs, which were directed against MALAT1 and injected every second week for 12 weeks, did not significantly affect plaque load or plaque size. To explain the discrepant results, we analyzed the expression of MALAT1, which was fully deleted in all analyzed cell types and tissues obtained from MALAT1-/- mice, whereas GapmeR-MALAT1 treatment efficiently silenced MALAT1 expression in all organs except circulating and splenic monocytes. These data suggest that inhibition of MALAT1 in inflammatory cells, which is not sufficiently accomplished by MALAT1 GapmeRs, may be necessary to modulate atherosclerotic disease progression. In line with this, infiltration of CD45+ cells was significantly augmented in MALAT1-/-ApoE-/- mice (+35.5+8.6%, n = 10, p&lt;0.05) but not in GapmeR-treated ApoE-/- mice (-5.6+12.3%, n=10, ns). Moreover, MALAT1 deletion significantly increased macrophages (+60.4+22.8%, n=10, p&lt;0.05) and dendritic cells in the spleen (+37.4+17.5%, n=10) and augmented circulating monocytes (+70.2+70.2%, n=5, ns). In conclusion, we show that genetic deletion but not pharmacological inhibition of MALAT1 enhances atherosclerotic lesion formation and augments splenic monocytes and hematopoietic cell recruitment to atherosclerotic plaques. The causal involvement of MALAT1 expression in hematopoietic cells in atherogenesis is currently elucidated by bone marrow transplantation experiments.
Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding
Authors: Shashank Tripathi, Marie O. Pohl, Yingyao Zhou, Ariel Rodriguez-Frandsen, Guojun Wang, David A. Stein, Hong M. Moulton, Paul DeJesus, Jianwei Che, Lubbertus C.F. Mulder, Emilio Yángüez, Dario Andenmatten, Lars Pache, Balaji Manicassamy, Randy A. Albrecht, Maria G. Gonzalez, Quy Nguyen, Abraham Brass, Stephen Elledge, Michael White, Sagi Shapira, Nir Hacohen, Alexander Karlas, Thomas F. Meyer, Michael Shales, Andre Gatorano, Jeffrey R. Johnson, Gwen Jang, Tasha Johnson, Erik Verschueren, Doug Sanders, Nevan Krogan, Megan Shaw, Renate König, Silke Stertz, Adolfo García-Sastre, Sumit K. Chanda
Journal: Cell Host & Microbe (2015)
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
Authors: R de Waal Malefyt, J Abrams, B Bennett, C G Figdor, J E de Vries
Journal: The Journal of Experimental Medicine (1991)

In the present study we demonstrate that human monocytes activated by lipopolysaccharides (LPS) were able to produce high levels of interleukin 10 (IL-10), previously designated cytokine synthesis inhibitory factor (CSIF), in a dose dependent fashion. IL-10 was detectable 7 h after activation of the monocytes and maximal levels of IL-10 production were observed after 24-48 h. These kinetics indicated that the production of IL-10 by human monocytes was relatively late as compared to the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, tumor necrosis factor alpha (TNF alpha), and granulocyte colony-stimulating factor (G-CSF), which were all secreted at high levels 4-8 h after activation. The production of IL-10 by LPS activated monocytes was, similar to that of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), and G-CSF, inhibited by IL-4. Furthermore we demonstrate here that IL-10, added to monocytes, activated by interferon gamma (IFN-gamma), LPS, or combinations of LPS and IFN-gamma at the onset of the cultures, strongly inhibited the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, GM-CSF, and G-CSF at the transcriptional level. Viral-IL-10, which has similar biological activities on human cells, also inhibited the production of TNF alpha and GM-CSF by monocytes following LPS activation. Activation of monocytes by LPS in the presence of neutralizing anti-IL-10 monoclonal antibodies resulted in the production of higher amounts of cytokines relative to LPS treatment alone, indicating that endogenously produced IL-10 inhibited the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, GM-CSF, and G-CSF. In addition, IL-10 had autoregulatory effects since it strongly inhibited IL-10 mRNA synthesis in LPS activated monocytes. Furthermore, endogenously produced IL-10 was found to be responsible for the reduction in class II major histocompatibility complex (MHC) expression following activation of monocytes with LPS. Taken together our results indicate that IL-10 has important regulatory effects on immunological and inflammatory responses because of its capacity to downregulate class II MHC expression and to inhibit the production of proinflammatory cytokines by monocytes.